Lilly Reports Solid First-Quart...(ma as if the ICOS acquisition was c...)

was completed on January 1, 2007 - (.01)

---- ----

Totals $.92 $.83 11 %

---- ----

Zyprexa

In the first quarter of 2008, Zyprexa sales totaled $1.120 billion, a 1 percent increase compared with the first quarter of 2007. U.S. sales of Zyprexa decreased 5 percent, to $499.3 million, due to decreased demand. Zyprexa sales in international markets increased 6 percent, to $620.9 million, driven by the favorable impact of foreign exchange rates. Demand outside the U.S. decreased slightly, as the impact of generic competition in Canada and Germany offset growth in Japan and several European markets.

Cymbalta

For the first quarter of 2008, Cymbalta generated $605.1 million in sales, an increase of 37 percent compared with the first quarter of 2007. U.S. sales of Cymbalta increased 32 percent, to $511.1 million, driven primarily by strong demand. Sales outside the U.S. were $94.0 million, an increase of 69 percent, driven primarily by higher demand, as well as the favorable impact of foreign exchange rates.

Gemzar

Gemzar sales totaled $426.2 million in the first quarter on 2008, an increase of 13 percent from the first quarter of 2007. Sales in the U.S. increased 8 percent, to $175.7 million, due to higher prices and increased demand, while sales outside the U.S. increased 17 percent, to $250.5 million, as a result of the favorable impact of foreign exchange rates and increased demand.

Humalog

For the first quarter of 2008, worldwide Humalog sales increased 20 percent, to $407.4 million. Sales in the U.S. increased 13 percent to $238.6 million, driven by higher demand and increased prices. Sales outside the U.S. increased 31 percent to $168.8 million, driven by strong demand and the favorable impact
'/>"/>